Singapore: Japan headquartered Takeda Pharmaceutical has expanded its operations in Singapore in order to focus on emerging markets and to consolidate and streamline its Asia operations.

Dr Beh Swan Gin, chairman, Singapore Economic Development Board, said, "EDB welcomes Takeda's decision to make Singapore its Emerging Markets Business Unit headquarters. Singapore has become the preferred location for international companies to locate their regional headquarters in Asia and South East Asia by harnessing our connectivity to the markets around us and our attractive work-live-play-learn environment. But we are not resting on our laurels as we are actively expanding the network and sophistication of professional services firms that support senior decision makers in these regional headquarters."

The new office will house Takeda emerging markets business unit, including Asia-Pacific, as well as the Takeda vaccine business unit and regional research and development center.

"Our patients are the core of what we do at Takeda. Our new space in Singapore will allow us to more quickly address evolving market needs throughout the rapidly growing Emerging Markets, including Asia-Pacific," said Mr Giles Platford, president, emerging markets business unit. "It gives us close-to-door access to important market information that will help accelerate the development of medicines needed for battling regional and global health issues."